United Therapeutics Corp’s filing revealed that its Chairperson & CEO ROTHBLATT MARTINE A unloaded Company’s shares for reported $1.2 million on Aug 12 ’24. In the deal valued at $334.14 per share,3,600 shares were sold. As a result of this transaction, ROTHBLATT MARTINE A now holds 130 shares worth roughly $42066.7.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ROTHBLATT MARTINE A sold 3,600 shares, generating $1,189,712 in total proceeds. Upon selling the shares at $330.48, the Chairperson & CEO now owns 130 shares.
Before that, ROTHBLATT MARTINE A sold 3,600 shares. United Therapeutics Corp shares valued at $1,182,205 were divested by the Chairperson & CEO at a price of $328.39 per share. As a result of the transaction, ROTHBLATT MARTINE A now holds 130 shares, worth roughly $42066.7.
Morgan Stanley downgraded its United Therapeutics Corp [UTHR] rating to an Equal-weight from a an Overweight in a research note published on July 11, 2024; the price target was increased to $321 from $310. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Neutral”. Leerink Partners began covering UTHR with “an Outperform” recommendation on February 05, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated UTHR as “an Overweight”.
Price Performance Review of UTHR
On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -3.05% to $323.59. Over the last five days, the stock has gained 0.51%. United Therapeutics Corp shares have risen nearly 47.16% since the year began. Nevertheless, the stocks have risen 36.08% over the past one year. While a 52-week high of $343.98 was reached on 07/25/24, a 52-week low of $208.62 was recorded on 02/08/24. SMA at 50 days reached $314.66, while 200 days put it at $254.85.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 314.35, which if violated will result in even more drops to 305.10. On the upside, there is a resistance level at 335.79. A further resistance level may holdings at 347.98. The Relative Strength Index (RSI) on the 14-day chart is 49.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.01%. Stochastics%K at 56.53% indicates the stock is a holding.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on
The most recent change occurred on December 06, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $320 price target.
